The paradigm shift to an “open” model in drug development

The rising cost of healthcare, the rising cost for drug development, the patent cliff for Big pharma, shorter patent protection, decrease reimbursement, and the recession have made it more difficult for the pharmaceutical and biotechnology industry to develop drugs. Due to the unsustainable amount o...

Descripción completa

Detalles Bibliográficos
Autor principal: Au, Regina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Special Issue - Genomic Knowledge Sharing
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888825/
https://www.ncbi.nlm.nih.gov/pubmed/27294020
http://dx.doi.org/10.1016/j.atg.2014.09.001
_version_ 1782434907904016384
author Au, Regina
author_facet Au, Regina
author_sort Au, Regina
collection PubMed
description The rising cost of healthcare, the rising cost for drug development, the patent cliff for Big pharma, shorter patent protection, decrease reimbursement, and the recession have made it more difficult for the pharmaceutical and biotechnology industry to develop drugs. Due to the unsustainable amount of time and money in developing a drug that will have a significant return on investment (ROI) it has become hard to sustain a robust pipeline. The industry is transforming its business model to meet these challenges. In essence a paradigm shift is occurring; the old “closed” model is giving way to a new “open” business model.
format Online
Article
Text
id pubmed-4888825
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-48888252016-06-10 The paradigm shift to an “open” model in drug development Au, Regina Appl Transl Genom Special Issue - Genomic Knowledge Sharing The rising cost of healthcare, the rising cost for drug development, the patent cliff for Big pharma, shorter patent protection, decrease reimbursement, and the recession have made it more difficult for the pharmaceutical and biotechnology industry to develop drugs. Due to the unsustainable amount of time and money in developing a drug that will have a significant return on investment (ROI) it has become hard to sustain a robust pipeline. The industry is transforming its business model to meet these challenges. In essence a paradigm shift is occurring; the old “closed” model is giving way to a new “open” business model. Elsevier 2014-09-16 /pmc/articles/PMC4888825/ /pubmed/27294020 http://dx.doi.org/10.1016/j.atg.2014.09.001 Text en © 2014 The Author http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Special Issue - Genomic Knowledge Sharing
Au, Regina
The paradigm shift to an “open” model in drug development
title The paradigm shift to an “open” model in drug development
title_full The paradigm shift to an “open” model in drug development
title_fullStr The paradigm shift to an “open” model in drug development
title_full_unstemmed The paradigm shift to an “open” model in drug development
title_short The paradigm shift to an “open” model in drug development
title_sort paradigm shift to an “open” model in drug development
topic Special Issue - Genomic Knowledge Sharing
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888825/
https://www.ncbi.nlm.nih.gov/pubmed/27294020
http://dx.doi.org/10.1016/j.atg.2014.09.001
work_keys_str_mv AT auregina theparadigmshifttoanopenmodelindrugdevelopment
AT auregina paradigmshifttoanopenmodelindrugdevelopment

Ejemplares similares